Liraglutide
Based on 40 publication(s) in Google Scholar
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 204656-20-2
- Formule: C172H265N43O51
- Masse moléculaire:3751.20
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Liraglutide
More- Cell. 2025 Dec 24;188(26):7547-7570.e45 [Abstract]
- Nat Metab. 2024 May 20. [Abstract]
- Neuron. 2026 Mar 27:S0896-6273(26)00125-X. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Sci Adv. 2022 Jul 22;8(29):eabn3773. [Abstract]
- Cardiovasc Diabetol. 2024 Jul 5;23(1):236. [Abstract]
- Brain Behav Immun. 2026 Jan 22:134:106295. [Abstract]
- Anal Chem. 2025 Jul 1;97(25):13465-13473. [Abstract]
- Life Sci. 2025 Aug 15:123912. [Abstract]
- J Nutr Biochem. 2025 Nov 26:110206. [Abstract]
- Int J Mol Sci. 2019 Apr 2;20(7). pii: E1629. [Abstract]
- Front Pharmacol. 2020 Feb 28;11:136. [Abstract]
- Int Immunopharmacol. 2025 Dec 11:169:116010. [Abstract]
- Int Immunopharmacol. 2024 Sep 27;142(Pt B):113258. [Abstract]
- Obesity. 2023 Nov;31(11):2676-2688. [Abstract]
- FASEB J. 2025 Nov 30;39(22):e71229. [Abstract]
- iScience. 2025 Apr 3;28(5):112344. [Abstract]
- iScience. 2023 Jan 7;26(2):105938. [Abstract]
- ACS Med Chem Lett. 2026 May 4;17(5):963-972. [Abstract]
- Sci Rep. 2025 Jan 12;15(1):1754. [Abstract]
- Sci Rep. 2024 Jun 14;14(1):13726. [Abstract]
- Biomedicines. 2023 Sep 27;11(10):2651. [Abstract]
- J Biol Chem. 2021 Jan-Jun:296:100807. [Abstract]
- Cardiovasc Toxicol. 2023 Apr;23(3-4):161-175. [Abstract]
- J Invest Surg. 2022 May;35(5):1012-1020. [Abstract]
- Microb Pathog. 2021 Jan;150:104645. [Abstract]
- Mol Med Rep. 2016 Oct;14(4):3662-8. [Abstract]
- Am J Physiol Renal Physiol. 2020 Sep 1;319(3):F458-F468. [Abstract]
- J Biochem Mol Toxicol. 2026 Jun;40(6):e70913. [Abstract]
- Exp Biol Med. 2019 Oct;244(14):1193-1201. [Abstract]
- Clin Exp Pharmacol Physiol. 2024 Dec;51(12):e70003. [Abstract]
- Am J Physiol Regul Integr Comp Physiol. 2024 Oct 1;327(4):R410-R422. [Abstract]
- In Vitro Cell Dev Biol Anim. 2024 Oct;60(9):1046-1057. [Abstract]
- Cardiovasc Prev Pharmacother. 2025 Jul 24;7(3):61-72.
- bioRxiv. 2025 Jun 08.
- bioRxiv. 2025 Mar 4:2025.02.27.640645. [Abstract]
- ChemRxiv. 2025 Feb 25.
- Res Sq. 2024 Jun 13.
- SSRN. 2024 May 30.
- Research Square Preprint. 2021 Dec.
Customer Validation & Images
-
IF
-
Others
-
RT-PCR
-
WB
-
WB
Activité biologique
GLP-1 receptor[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
65.7 pM
Compound: Liraglutide
|
Agonist activity at human GLP1 receptor expressed in HEK293 cells assessed as induction of cAMP levels after 20 mins by time-resolved fluorescence analysis
Agonist activity at human GLP1 receptor expressed in HEK293 cells assessed as induction of cAMP levels after 20 mins by time-resolved fluorescence analysis
|
[PMID: 31471103] |
| HEK293 | EC50 |
9.3 pM
Compound: liraglutide
|
Activation of human GLP-1 receptor overexpressed in HEK293 cells assessed as cAMP accumulation after 20 mins by HTRF assay
Activation of human GLP-1 receptor overexpressed in HEK293 cells assessed as cAMP accumulation after 20 mins by HTRF assay
|
[PMID: 24308627] |
Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{Lys(γGlu-C16 acid)}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
HAEGTFTSDVSSYLEGQAA-{Lys(γGlu-C16 acid)}-EFIAWLVRGRG
Chemical Information
-
CAS No. 204656-20-2
-
Appearance Solid
-
Masse moléculaire 3751.20
-
Formule C172H265N43O51
-
Color White to off-white
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (40)
-
Journal Impact Factor
-
Most Recent
-
Cell
In vivo transcriptomic, functional, circuit-based, and translational analyses of enteric neurons. [Abstract]2025 Dec 24;188(26):7547-7570.e45 PMID: 41406962 -
Nat Metab
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice. [Abstract]2024 May 20. PMID: 38769396 -
Neuron
A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice. [Abstract]2026 Mar 27:S0896-6273(26)00125-X. PMID: 41903537 -
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334 -
Sci Adv
14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing. [Abstract]2022 Jul 22;8(29):eabn3773. PMID: 35867787
Liraglutide purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Jul 22;8(29):eabn3773. [Abstract]
Representative images of mouse islets immuno stained for insulin (red), 14-3-3-zeta (green), and DAPI (blue) in β cell GLP-1R WT and KO mice treated with saline (CTRL) or Liraglutide (LIRA) (100 nM).
Liraglutide purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Jul 22;8(29):eabn3773. [Abstract]
Insulin secretion from islets isolated from β cell GLP-1R WT and KO mice in response to 11.1 mM Glucose with or without 100 nM Liraglutide.
Liraglutide purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Jul 22;8(29):eabn3773. [Abstract]
α Cell Pcsk1 mRNA expression following treatment with conditioned media generated from islets of saline- and liraglutide-treated WT mice following 15 min and 2 hours of incubation with saline or Liraglutide (100 nM).
-
Cardiovasc Diabetol
Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization. [Abstract]2024 Jul 5;23(1):236. PMID: 38970123 -
Brain Behav Immun
Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression. [Abstract]2026 Jan 22:134:106295. PMID: 41580096 -
Anal Chem
Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics. [Abstract]2025 Jul 1;97(25):13465-13473. PMID: 40521838 -
Life Sci
Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation. [Abstract]2025 Aug 15:123912. PMID: 40819789 -
J Nutr Biochem
Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in mouse models of type 2 diabetes. [Abstract]2025 Nov 26:110206. PMID: 41314560 -
Int J Mol Sci
2019 Apr 2;20(7). pii: E1629. PMID: 30986904 -
Front Pharmacol
The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome. [Abstract]2020 Feb 28;11:136. PMID: 32184723 -
Int Immunopharmacol
GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway. [Abstract]2025 Dec 11:169:116010. PMID: 41386184 -
Int Immunopharmacol
Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. [Abstract]2024 Sep 27;142(Pt B):113258. PMID: 39340991 -
Obesity
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model. [Abstract]2023 Nov;31(11):2676-2688. PMID: 37840407 -
FASEB J
Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy. [Abstract]2025 Nov 30;39(22):e71229. PMID: 41246995 -
iScience
2025 Apr 3;28(5):112344. PMID: 40276762 -
iScience
2023 Jan 7;26(2):105938. PMID: 36718359 -
ACS Med Chem Lett
In Vitro Characterization of Agonist and Antagonist Peptide Binding Interaction Kinetics to GLP-1R in HEK293T Cells Using Surface Plasmon Resonance Microscopy. [Abstract]2026 May 4;17(5):963-972. PMID: 42157826 -
Sci Rep
Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway. [Abstract]2025 Jan 12;15(1):1754. PMID: 39799153 -
Sci Rep
Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo. [Abstract]2024 Jun 14;14(1):13726. PMID: 38877189 -
Biomedicines
2023 Sep 27;11(10):2651. PMID: 37893024 -
J Biol Chem
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. [Abstract]2021 Jan-Jun:296:100807. PMID: 34022222 -
Cardiovasc Toxicol
Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway. [Abstract]2023 Apr;23(3-4):161-175. PMID: 36934206 -
J Invest Surg
HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB. [Abstract]2022 May;35(5):1012-1020. PMID: 34670452 -
Microb Pathog
The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice. [Abstract]2021 Jan;150:104645. PMID: 33285220 -
Mol Med Rep
Liraglutide attenuates the osteoblastic differentiation of MC3T3‑E1 cells by modulating AMPK/mTOR signaling. [Abstract]2016 Oct;14(4):3662-8. PMID: 27600753
Liraglutide purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2016 Oct;14(4):3662-8. [Abstract]
Liraglutide (0-4 nM; 14 days). Relative protein expression of Alp and OC was analyzed by western blot and quantified relative to GAPDH.
-
Am J Physiol Renal Physiol
Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling. [Abstract]2020 Sep 1;319(3):F458-F468. PMID: 32715762
Liraglutide purchased from MedChemExpress. Usage Cited in: Am J Physiol Renal Physiol. 2020 Sep 1;319(3):F458-F468. [Abstract]
Representative Western blot showing FN protein abundance in HMCs cultured in media containing 5.5 mM glucose (NG) or 5.5 mM glucose + 19.5 mM mannitol (NG+M) or 25 mM glucose (HG) in the absence or presence of Liraglutide at different concentrations (1 nM, 10 nM, 100 nM, 1000 nM) for 24h.
-
J Biochem Mol Toxicol
The GLP-1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC-3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and Adipokines. [Abstract]2026 Jun;40(6):e70913. PMID: 42152582 -
Exp Biol Med
Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel. [Abstract]2019 Oct;244(14):1193-1201. PMID: 31510798 -
Clin Exp Pharmacol Physiol
GLP-1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy. [Abstract]2024 Dec;51(12):e70003. PMID: 39477212 -
Am J Physiol Regul Integr Comp Physiol
Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-kappaB pathway in diabetic kidney disease. [Abstract]2024 Oct 1;327(4):R410-R422. PMID: 39133777 -
In Vitro Cell Dev Biol Anim
Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway. [Abstract]2024 Oct;60(9):1046-1057. PMID: 39039329 -
-
-
bioRxiv
Unveiling the Hidden: Dissecting Liraglutide Oligomerization Dual Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics. [Abstract]2025 Mar 4:2025.02.27.640645. PMID: 40093118 -
-
-
-
Solvant et solubilité
0.1 M NaOH : ≥ 12.5 mg/mL (3.33 mM)
H2O : 9.52 mg/mL (2.54 mM; adjust pH to 3 with 1 M HCl)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocole
Raw264.7 macrophage cells are cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in a humidified 37°C incubator with 5% CO2. The cells are incubated with oxLDL (50 μg/mL), Liraglutide (0.1, 0.5, 1 and 2 nM) or Exendin-3 (9-39) (1, 10 and 100 nM) alone, or in combination[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wang Y,et al. Transformation of oligomers of lipidated peptide induced by change in pH.Mol Pharm. 2015 Feb 2;12(2):411-9. [Content Brief]
[2]. Wang YG, et al. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway.J Geriatr Cardiol. 2015 Jul;12(4):410-416. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / 0.1 M NaOH | 1 mM | 0.2666 mL | 1.3329 mL | 2.6658 mL | 6.6645 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz